Subscribe
marianvejcik-istockphoto-com-gavel-uk-
27 October 2017Big Pharma

Teva suffers defeat as Copaxone claims invalidated

The English High Court has invalidated two patent claims protecting Copaxone (glatiramer acetate), a billion-dollar drug marketed by Teva.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Teva survives Copaxone patent challenge
22 May 2015   Teva has successfully defended two patents related to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate) at the English High Court.
Americas
Teva to appeal against invalidation of Copaxone patents
31 January 2017   Teva will appeal against a decision which saw the invalidation of four patents covering its multiple sclerosis drug Copaxone.
Big Pharma
Teva drops Copaxone generic suit against Mylan
12 December 2017   Teva has dropped its litigation over two US patents against Mylan, after a district court adopted Mylan’s interpretation of the patents.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Big Pharma
Teva survives Copaxone patent challenge
22 May 2015   Teva has successfully defended two patents related to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate) at the English High Court.
Americas
Teva to appeal against invalidation of Copaxone patents
31 January 2017   Teva will appeal against a decision which saw the invalidation of four patents covering its multiple sclerosis drug Copaxone.
Big Pharma
Teva drops Copaxone generic suit against Mylan
12 December 2017   Teva has dropped its litigation over two US patents against Mylan, after a district court adopted Mylan’s interpretation of the patents.

More on this story

Big Pharma
Teva survives Copaxone patent challenge
22 May 2015   Teva has successfully defended two patents related to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate) at the English High Court.
Americas
Teva to appeal against invalidation of Copaxone patents
31 January 2017   Teva will appeal against a decision which saw the invalidation of four patents covering its multiple sclerosis drug Copaxone.
Big Pharma
Teva drops Copaxone generic suit against Mylan
12 December 2017   Teva has dropped its litigation over two US patents against Mylan, after a district court adopted Mylan’s interpretation of the patents.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent